This is a news story, published by CNBC, that relates primarily to Eisai news.
For more Eisai news, you can click here:
more Eisai newsFor more biology news, you can click here:
more biology newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about
drug Leqembi. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Alzheimer news, Leqembi news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
breakthrough AlzheimerCNBC
•89% Informative
Leqembi slowed Alzheimer's disease progression in patients over three years , according to new data presented by Japanese drugmaker Eisai at a medical conference.
The health of Alzheimer's patients who take the therapy worsens after they stop treatment.
Nearly 7 million Americans have the condition, the fifth -leading cause of death for adults over 65 .
The drug is a monoclonal antibody that targets toxic plaques in the brain.
A sub-study of the trial partly examined patients with no or very low levels of another protein that builds up in the brain called tau.
After three years on Leqembi , 59% of people with low tau levels did not see their Alzheimer's progress.
A little over half of that patient population actually saw their condition improve.
VR Score
93
Informative language
95
Neutral language
65
Article tone
semi-formal
Language
English
Language complexity
54
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
4
Source diversity
4
Affiliate links
no affiliate links